• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 16.48
  • VXN 19.83
  • VXO 17.26
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
VIVO (Meridian Bioscience Inc.)
Last Trade 16.83 Dividend/Share 0.5 PE Ratio 22.74
Date March 22-2019 Dividend Yield 2.921 Return on Assets 10.22
Change -0.29 ExDividend Date 2019-02-01 Return on Capital null
Bid 0 Latest EPS 0.56 Price/Sale 3.395
Ask 0 LatestEPS Date 2018-09-30 Price to Book 4.04
Volume 14095 EPS ttm 0.740 Institutional % 132.8
Avg Volume 0.29M Shares Outstanding 42.49M Insider % 3.9
Open 17.03 Float 40.85M Short Ratio null
Prev Close 17.12 Return On Equity 14.6 5 Year Change % -0.079
High 17.2 Consensus EPS 0.16 2 Year Change % 0.404
Low 16.83 No. of Estimate 3.000 1 Year Change % 0.186
52 Week High 19.84 EPS Surprise $ null YTD Change % 0.006
52 Week Low 13.75 EPS Surprise Percent 25 6 Month Change % 0.123
52 Week Change 18.973 EBITDA 0M 3 Month Change % 0.028
50 Day MA 16.55767 Revenue 0M 1 Month Change % -0.024
200 Day MA Gross Profit 0M 5 Day Change % 0.029
Market Cap 727.42M Cash 0M 30 Day Change % 0.040
Beta 0.480357 Debt 0M Stock Exchange Nasdaq Global Select
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Meridian Bioscience, Inc. operates as an integrated life science company. The company primarily engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases. Its diagnostic test kits utilize immunodiagnostic technologies, which test samples of blood, urine, stool, and other body fluids or tissues for the presence of antigens and antibodies of specific infectious diseases. The immunodiagnostic technologies include enzyme immunoassay, immunofluorescence, particle agglutination/aggregation, immunodiffusion, complement fixation, and chemical stains. The company also provides transport media that store and preserve specimen samples from patient collection to laboratory testing. In addition, Meridian Bioscience manufactures and distributes bulk antigens, antibodies, and reagents used by researchers and other diagnostic manufacturers. Further, it involves in the contract development and manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Meridian Bioscience markets its diagnostic test kits through direct sales force and independent distributors to reference laboratories and hospitals primarily in the United States, Canada, Belgium, France, Holland, Italy, Africa, and the Middle East. The company was founded in 1976 and is based in Cincinnati, Ohio.